3.28
-0.1(-2.96%)
Currency In USD
| Previous Close | 3.38 |
| Open | 3.41 |
| Day High | 3.41 |
| Day Low | 3.2 |
| 52-Week High | 9.84 |
| 52-Week Low | 2.39 |
| Volume | 141,776 |
| Average Volume | 142,641 |
| Market Cap | 3.8M |
| PE | -1.64 |
| EPS | -2 |
| Moving Average 50 Days | 3.19 |
| Moving Average 200 Days | 5.11 |
| Change | -0.1 |
If you invested $1000 in Chemomab Therapeutics Ltd. (CMMB) since IPO date, it would be worth $4.75 as of October 17, 2025 at a share price of $3.28. Whereas If you bought $1000 worth of Chemomab Therapeutics Ltd. (CMMB) shares 5 years ago, it would be worth $44.96 as of October 17, 2025 at a share price of $3.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 21, 2025 12:00 PM GMT
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announce
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
GlobeNewswire Inc.
Jun 30, 2025 12:00 PM GMT
SPRING Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improve
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue— TEL AVIV, Israel, June 11,